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Abstract  
 
Background:  Atrial fibrillation (AF) and heart failure frequently coexist and are associated 
with increased morbidity and mortality.  We investigated the prognosis of anticoagulated 
patients with permanent AF and non-permanent AF according to pre-existing heart failure in 
the AMADEUS trial.  
Methods:  The primary outcome was a composite of cardiovascular death and stroke or 
systemic embolism (SSE), analysed using a Cox proportional hazards model, adjusted for 
baseline age, gender, diabetes, hypertension, creatinine and previous cardiovascular diseases.  
The median follow-up was 11.6 months (IQR 6.2-15.2). 
Results:  Non-permanent AF was present in 2072 patients (46% of cohort), of which 339 
(16%) had pre-existing HF.  2484 patients had permanent AF (54% of cohort), with a higher 
burden of heart failure including 730 patients (29%); p<0.001.  Overall, death due to 
cardiovascular causes occurred in 57 patients and 55 had SSE (1.4/100 person-years for each).  
Overall, the adjusted incidence of the composite outcome was higher in patients with 
permanent AF compared to non-permanent AF.  In multivariate analysis, permanency of AF, 
creatinine, prior cerebrovascular events and previous coronary disease were independently 
associated with the primary outcome.  The hazard ratio for permanent versus non-permanent 
AF was 1.68 (95% CI 1.08-2.55; p=0.02).  The presence of heart failure attenuated the risk of 
adverse outcomes in a similar way in both permanent and non-permanent AF (interaction p-
value=0.76). 
Conclusion:  The risk of cardiovascular death, stroke or systemic embolism is higher in 
anticoagulated patients with permanent compared to non-permanent AF, regardless of 
concomitant heart failure. 
 
Introduction 
 
Non-valvular atrial fibrillation (AF) increases the risk of stroke and systemic embolism (SSE), 
leading to substantial morbidity and mortality.1  Whether the risk of stroke is affected by the 
type, duration, and frequency of AF has been debated for several years.  Pooled analysis of 
the Stroke Prevention in Atrial Fibrillation (SPAF) trials demonstrated a comparable risk of 
stroke in patients with paroxysmal and sustained AF treated with aspirin.2 3, 4  In contrast, 
recently published data from the ROCKET-AF trial identified a higher rate of adverse 
outcomes in anticoagulated patients with persistent compared to paroxysmal AF, with 
borderline statistical significance for SSE (2.2 versus 1.7 per 100 patient-years; p=0.048) and 
significantly higher all-cause mortality (4.8 versus 3.5 per 100 patient-years; p=0.006).5   
Similar findings of increased stroke risk have been published from other studies using both 
vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOAC), including the 
SPORTIF and ARISTOTLE trials.6, 7  Global surveys suggest that permanent AF is the most 
common type, accounting for around 50% of AF patients who also have a substantial burden 
of co-morbidities.  This includes heart failure, present in 56% of patients with permanent AF, 
compared to 33% in paroxysmal and 44% in persistent AF.8   
 
Practice guidelines on AF management address the prevention of SSE regardless of the type 
of AF, based on known risk factors in this patient population.9, 10  The CHA2DS2-VASc score 
is a commonly-used risk prediction score for SSE, focusing on clinical risk factors.11  The “C” 
criterion represents the higher stroke risk associated with recent decompensated heart failure 
irrespective of ejection fraction (thus including heart failure with reduced and preserved 
ejection fraction, as well as moderate-severe left ventricular systolic impairment on 
echocardiography).12, 13  Moreover, the combination of AF and heart failure is associated with 
an increased risk of all-cause mortality and hospital admission, with numerous studies 
suggesting that AF may be associated with progression of heart failure.14-18  The impact of the 
type of AF on outcomes such as stroke and death in anticoagulated AF patients with and 
without heart failure remains controversial, particularly in regards to permanent compared to 
non-permanent AF.  As both incidence and prevalence of AF are rapidly increasing19, the 
burden of heart failure can be expected to rise proportionally.  To investigate these aspects 
further, we reviewed data from the AMADEUS trial (Evaluating the Use of SR34006 
Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation), a multicentre, 
randomized, open-label study comparing fixed-dose idraparinux with dose-adjusted VKA 
therapy in AF patients with an indication for long-term anticoagulation.20  We hypothesised 
that adverse outcomes would be more prevalent in permanent AF and aimed to assess the 
impact of heart failure in anticoagulated patients, accounting for the type of AF. 
 
  
Methods 
 
Study population 
The design of the AMADEUS trial has previously been described.20, 21  In brief, the 
AMADEUS trial was a multicentre, randomized, open-label non-inferiority study with 
blinded assessment of outcome that compared fixed-dose idraparinux with conventional 
anticoagulation by dose-adjusted oral VKA therapy for the prevention of thromboembolism 
in patients with AF.  Eligible patients had ECG-documented non-valvular AF and an 
indication for long-term anticoagulation, based on the presence of at least one of the 
following risk factors: previous ischemic stroke, transient ischemic attack (TIA) or systemic 
embolism, hypertension requiring drug treatment, left ventricular dysfunction, age >75 years, 
or age 65-75 with either diabetes mellitus or symptomatic coronary artery disease (CAD).  
Exclusion criteria included the inability to provide consent, contraindication or other 
requirement for anticoagulation, calculated creatinine clearance of <10 mL/min, 
breastfeeding, pregnancy and recent or anticipated invasive procedures with potential for 
uncontrolled bleeding.  We examined the population according to type of AF, considering 
non-permanent AF (comprising paroxysmal and persistent) versus permanent AF.  The 
presence of investigator-documented heart failure at baseline was used to sub-categorise the 
population. 
 
Definitions of endpoint 
This post-hoc analysis of the AMADEUS trial used pooled data from both the VKA and 
idraparinux arms on an intention to treat basis.  The primary outcome of this analysis was the 
composite of cardiovascular (CV) death and SSE.  Stroke included ischaemic, haemorrhagic 
or undefined causes that resulted in a focal neurological deficit of sudden onset, with a 
corresponding defect on brain imaging.  Systemic embolism was confirmed by angiography, 
surgery, or autopsy.  The safety outcome of the present analysis was major bleeding in the 
VKA arm of the trial, defined as bleeding that was fatal, intracranial or affecting another 
critical anatomical site, overt bleeding with a drop of haemoglobin ≥20 g/L or requiring 
transfusion of two or more units of erythrocytes.  All suspected outcome events were 
classified by the original AMADEUS central adjudication committee who were blinded to 
treatment assignment. 
 
Statistical analysis 
The characteristics of the patients are reported as percentages and mean ± standard deviation 
(SD).  Comparisons between patients with and without pre-existing heart failure were made 
using Fisher’s exact test when comparing categorical variables and t-tests or the Mann–
Whitney U-test, as appropriate for continuous variables.  Outcomes by type of AF 
(permanent AF versus non-permanent) were calculated by the overall rate of adverse events 
per 100 patient-years after adjustment for age and sex.  A Cox proportional hazard model was 
used to identify the independent characteristics associated with outcomes during follow-up.  
The multivariate model included adjustment for age, sex, creatinine (log-transformed), 
hypertension, diabetes mellitus and previous stroke/TIA/thromboembolism and CAD.  The 
results are expressed as hazard ratios (HR) and 95% confidence intervals (CI).  Schoenfeld 
residuals were used to confirm proportional hazards over time.  All interactions were 
evaluated in the multivariate Cox model, including two post-hoc defined exploratory analyses 
according to treatment allocation and time in therapeutic range (TTR) for those randomised 
to VKA.  The adjusted probabilities comparing permanent and non-permanent AF were 
analysed using an adjusted logistic regression model, with heart failure interaction 
determined using a likelihood ratio test.  Kaplan–Meier curves were assessed using a log-rank 
test.  A two-tailed p-value <0.05 was considered statistically significant.  Analyses were 
performed using SPSS (version 21) and Stata (version 13.1).  
Results 
 
Atrial fibrillation was present in 4556 patients.  Non-permanent AF accounted for 2072 
patients (46% of cohort), of which 339 (16%) had pre-existing heart failure.  Permanent AF 
was documented in 2484 patients (54% of cohort), with a higher burden of heart failure that 
included 730 patients (29%); p<0.001 compared to non-permanent AF.  Baseline 
characteristics according to type of AF are presented in Table 1.  Patients with permanent AF 
were older, with more men, a higher rate of diabetes, less hypertension and overall a 
marginally higher CHA2DS2-VASc score.  Patients with pre-existing heart failure had a 
higher frequency of men, diabetes, renal impairment and CAD than those without a history of 
heart failure (see Supplementary Table). 
 
Table 2 presents the outcomes observed over a median follow-up of 11.6 months 
(interquartile range [IQR] 6.2 to 15.2).  The primary composite outcome occurred in 68 
patients in permanent AF (3.0/100person-years) and 31 patients in non-permanent AF 
(1.7/100 person-years).  There were numerically more outcomes among those with permanent 
AF for each component of the primary outcome (CV death and SSE; see Table 2) but these 
differences were not significant.  The hazard ratio for the primary outcome comparing 
permanent versus non-permanent AF was 1.73 in univariate analysis (95% CI 1.13-2.64; 
p=0.01) and 1.66 following multivariate adjustment (95% CI 1.08-2.55; p=0.02); see Table 3.  
The Kaplan-Meier event curves are depicted in Figure 1 (log-rank p=0.01).  Other variables 
independently associated with the primary outcome were creatinine, prior cerebrovascular 
events and previous CAD.  In exploratory analyses, neither allocation to treatment arm (VKA 
or Idraparinux) nor TTR in VKA patients interacted with the association of AF type and the 
primary outcome (p=0.19 and 0.38 respectively). 
Due to the low number of events, we were limited in power to detect differences between 
permanent and non-permanent AF in the sub-groups with and without heart failure.  However, 
the same trend of an increase in adverse events in those with permanent AF compared to non-
permanent AF was evident, regardless of heart failure status (see Table 2).  The interaction p-
value between AF type and heart failure status for the primary outcome was 0.76.  Figure 2 
displays the adjusted probabilities of the primary outcome according to the four sub-groups, 
demonstrating a similar increase in adverse events with concomitant heart failure in both 
permanent and non-permanent AF. 
Bleeding outcomes in the warfarin arm of the trial are listed in Table 4.  Major bleeding, and 
a composite with CV death and SSE, were not significantly different between patients with 
permanent and non-permanent AF, irrespective of the presence of heart failure. 
 
  
Discussion 
 
Our analysis demonstrates that in anticoagulated patients, permanent AF is associated with a 
higher risk of the composite endpoint of CV death, stroke or systemic embolism compared to 
non-permanent forms of AF.  This finding was maintained even after adjustment for potential 
confounders that could influence the risk of events.  Importantly, we did not identify any 
interaction with pre-existing heart failure, confirming that the adverse risk associated with 
permanent AF is independent of heart failure status.   
 
Atrial fibrillation results in a considerable burden on patients and healthcare systems, leading 
to an increased risk of stroke, hospital admission and death.22  Permanent AF is the most 
common form and is associated with numerous other cardiovascular risk factors.8  The impact 
of AF, particularly in regard to type of AF, has previously been difficult to define due to 
variation in the use of anticoagulation, differences in comorbidities and the presence of heart 
failure.  Concomitant AF and heart failure are common in clinical practice and regardless of 
which comes first, patients have a much poorer prognosis.  The Framingham study showed 
that in AF patients, heart failure was associated with significantly increased mortality (HR 
2.7 in men [95% CI 1.9-3.7] and 3.1 in women [95% CI 2.2-4.2]).16  In a meta-analysis of 
heart failure patients, the presence of AF was associated with higher risk of death both in 
randomized trials and observational studies (odds ratio 1.40, 95% CI 1.32-1.48 and 1.14, 95% 
CI 1.03-1.26, respectively).23   
 
Activation of the renin-angiotensin system and chronic atrial stretch due to structural heart 
disease can lead to histological changes in the atria.24, 25  Subsequently, this atrial remodelling 
is more likely to be associated with longer AF episodes and other complications.26, 27  Indeed, 
Taillandier et al found that permanent AF in patients with heart failure is associated with a 
higher risk of death and hospitalization for heart failure, mostly in patients with preserved left 
ventricular ejection fraction.28  These results suggested that the duration of AF episodes 
might be a potential risk factor for adverse outcomes in patients with heart failure, in addition 
to comorbidities and hemodynamic status. 
 
In general, the duration of AF episodes leading to thrombus formation are poorly known, and 
therefore clinicians have usually been less likely to treat short and infrequent episodes of AF 
with oral anticoagulation than patients with persistent or permanent AF.29 30  In the 
Stockholm Cohort Study on Atrial Fibrillation, ischemic strokes were twice as common in 
paroxysmal AF than predicted in the general population, but the same in paroxysmal AF and 
permanent AF.31  Of note, anticoagulation with VKA was only prescribed at baseline in 28% 
and 49%, respectively, and none of these analyses included consistently anticoagulated 
patients.  In contrast, we were able to study the residual risk of adverse outcomes in 
anticoagulated patients.  Following consistent anticoagulation with either dose-adjusted 
warfarin or fixed-dose idraparinux, our data demonstrate that permanent AF was associated 
with worse outcomes.  Similarly, in sub-studies of recent randomised trials on non-VKA 
anticoagulants, patients with persistent or permanent AF had a significantly higher rate of 
thromboembolic events compared to those with paroxysmal AF.5, 7  
 
Heart failure attenuated the risk of adverse outcomes similarly in both permanent and non-
permanent AF patients.  In patients with AF, hearty failure has been strongly associated with 
SSE and mortality, and independently adds to risk prediction.13 32  However, the mechanisms 
underlying this association remain an area of ongoing research.  Future studies of heart 
failure and AF should consider these aspects to improve our understanding of their complex 
inter-relationship.18   Our findings suggest that regardless of other comorbidities such as heart 
failure, patients with permanent AF have considerable risk of residual morbidity and 
mortality, even after anticoagulation.  This finding has important implications for AF 
treatment strategies and necessitates on-going management and the identification of where 
residual risks can be reduced further after anticoagulation. 
 
 
Limitations 
These results are based on a post-hoc analysis of the AMADEUS trial, and should be 
interpreted as hypothesis-generating.  The AMADEUS population was at relatively low risk 
of both ischemic stroke and bleeding events compared with “real-world” patients, with 
limited statistical power for sub-group comparisons.  We accepted the definition of heart 
failure as defined in the AMADEUS trial but were unable to delineate those patients with 
reduced or preserved ejection fraction.  Nevertheless, stroke outcomes in AF patients do not 
appear to differ according to ejection fraction.12, 33 Data regarding heart failure therapies were 
also not available, which may have affected outcomes differently according to type of AF. 
 
 
  
Conclusion 
 
This post-hoc analysis of the AMADEUS trial confirms a significantly higher risk of 
cardiovascular death, stroke or systemic embolism in anticoagulated patients with permanent 
AF compared to non-permanent AF.  Concomitant heart failure attenuates the residual risk of 
adverse outcomes after anticoagulation similarly in both permanent and non-permanent AF. 
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Table 1: Baseline characteristics according to type of AF 
 Non-Permanent AF Permanent AF P value 
Number 2072 2484  
Age, years ± SD 69.0 ± 9.3 71.1 ± 8.7 <0.001 
Age >75 (%) 30.4 39.2 <0.001 
Gender, male (%) 62.4 69.9 <0.001 
Hypertension (%) 80.2 74.5 <0.001 
Diabetes mellitus (%) 18.0 20.9 0.01 
Previous stroke, TIA or TE (%) 24.4 23.4 0.44 
Coronary artery disease (%) 30.3 31.2 0.48 
Creatinine clearance ± SD  77.3 ± 30.5 75.8 ± 31.3 0.12 
>80 ml/min (%) 38.6 37.7  
50-80 ml/min (%) 43.8 43.4  
30-49 ml/min (%) 15.4 17.2  
<30 ml/min (%) 1.5 1.4  
Concurrent treatment    
Aspirin (%) 17.9 15.0 0.01 
Clopidogrel or ticagrelor (%) 1.9 1.1 0.04 
TTR in warfarin arm ± SD 0.56 ± 0.20 0.58 ± 0.20 0.002 
CHA2DS2-VASC score    
Mean ± SD 3.3 ± 1.5 3.5 ± 1.5 <0.001 
By category:   <0.001 
Score of 0 in men or 1 in 
women (%) 0 0  
Score of 1 in men (%) 10.8 7.4  
Score of 2 or more (%) 89.2 92.6  
 
TIA, transient ischemic attack; TE, thromboembolism; AF, atrial fibrillation; TTR, time in 
therapeutic range.  
Table 2: Outcomes according to type of AF at baseline 
 Non-permanent AF 
No. of events 
(/100 patient-years) 
Permanent AF 
No. of events 
(/100 patient-
years) 
Adjusted 
hazard ratio 
(95% CI)* 
p-value 
Whole group 
Number 2072 2484   
Combined CV 
death and SSE  31 (1.7) 68 (3.0) 1.59 (1.04-2.44) 0.03 
CV death 18 (1.0) 39 (1.7) 1.52 (0.86-2.66) 0.15 
SSE 16 (0.9) 29 (1.3) 1.38 (0.74-2.55) 0.31 
With pre-existing heart failure 
Number 339 730   
Combined CV 
death and SSE  8 (2.6) 24 (3.6) 1.28 (0.57-2.86) 0.55 
CV death 6 (2.0) 18 (2.7) 1.30 (0.51-3.28) 0.58 
SSE 4 (1.3) 6 (0.9) 0.66 (0.18-2.33) 0.51 
Without heart failure 
Number 1733 1754   
Combined CV 
death and SSE  23 (1.6) 44 (2.8) 1.62 (0.97-2.69) 0.06 
CV death 12 (0.8) 21 (1.3) 1.38 (0.68-2.83) 0.37 
SSE 12 (0.8) 23 (1.4) 1.71 (0.85-3.46) 0.13 
 
CV, cardiovascular; SSE, stroke and systemic embolus. 
 
 
 Table 3: Cox regression analysis for the primary composite outcome regardless of heart 
failure status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIA, transient ischemic attack; TE, thromboembolism.  
 Univariate Multivariate 
Risk factor HR (95% CI) p-value HR (95% CI) p-value 
Permanent versus non-
permanent AF 1.73 (1.13-2.64) 0.01 1.66 (1.08-2.55) 0.02 
Creatinine 0.27 (0.17-0.43) <0.001 0.35 (0.19-0.66 0.001 
Prior stroke/TIA/TE 2.14 (1.43-3.20) <0.001 1.97 (1.31-2.96) 0.001 
Coronary artery disease 1.94 (1.31-2.88) 0.001 1.72 (1.14-2.57) 0.009 
Age 1.06(1.03-1.10) 0.001 1.02 (0.99-1.05) 0.31 
Sex 1.22(0.75-1.98) 0.42 1.26 (0.81-1.95) 0.31 
Hypertension 0.98 (0.62-1.55) 0.92 1.23 (0.77-1.97) 0.38 
Diabetes mellitus 1.04 (0.64-1.71) 0.86 0.97 (0.59-1.59) 0.90 
Table 4: Bleeding outcomes in the warfarin arm  
 
 
CV, cardiovascular; SSE, stroke and systemic embolus. 
 
 
  
 With pre-existing heart failure (n=541) Without heart failure (n=1744) 
 
Non-permanent AF 
No. of events 
(%/100 patient-
years) 
Permanent AF 
No. of events 
(%/100 patient-
years) 
Unadjusted 
p-value 
 
Non-permanent 
AF 
 No. of events 
(%/100 patient-
years) 
Permanent AF 
No. of events 
(%/100 patient-
years) 
Unadjuste
d p-value 
 
Number 166 375  861 883  
Major 
bleeding 2 (1.3) 6 (1.7) 1.00 8 (1.1) 13 (1.6) 0.38 
Composite of  
major 
bleeding, CV 
death or SSE 
7 (4.5) 19 (5.3) 0.83 23 (3.0) 32 (3.9) 0.28 
Supplementary Table: Baseline characteristics according to heart failure status 
 No prior 
heart failure 
Pre-existing heart 
failure 
P value 
Number 3487 1069  
Gender, male (%) 63.3 76.9 <0.001 
Age, years ± SD 70.3 ± 8.9 69.5 ± 9.6 0.01 
Age >75 (%) 35.7 33.4 0.16 
Hypertension (%) 80.6 65.6 <0.001 
Diabetes mellitus (%) 18.4 23.5 <0.001 
Previous stroke, TIA or TE (%) 25.4 18.6 <0.001 
Coronary artery disease (%) 26.4 45.0 <0.001 
Creatinine clearance ± SD  77.1 ± 30.9 74.5 ± 31.1 0.003 
>80 ml/min (%) 38.7 36.3 <0.001 
50-80 ml/min (%) 44.3 41.2  
30-49 ml/min (%) 15.3 20.0  
<30 ml/min (%) 1.2 2.3  
Type of AF   <0.001 
Permanent AF (%) 50.3 68.3  
Non-permanent AF (%) 49.7 31.7  
Concurrent treatment    
Aspirin (%) 15.2 19.9 <0.001 
Clopidogrel or ticagrelor (%) 1.4 1.7 0.56 
TTR in warfarin arm ± SD 0.58 ± 0.20 0.56 ± 0.22 0.07 
CHA2DS2-VASC score    
Mean ± SD 3.3 ± 1.5 4.0 ± 1.6 <0.001 
 
TIA, transient ischemic attack; TE, thromboembolism. 
 
 
 
 
 
 
 
 
Figure legends 
 
Figure 1: 
Kaplan Meier event curves for cardiovascular death, stroke or systemic embolism by type of AF  
 
Figure 2:  
Adjusted probabilities for cardiovascular death, stroke or systemic embolism according to type of 
AF and heart failure status 
  
Figure 1 
 
 
 
  
Figure 2 
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